NASDAQ · Biotechnology · USD

Gyre Therapeutics, Inc. (GYRE) Stock Analysis

Gyre Therapeutics, Inc. (GYRE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GYRE

$5.90

−$0.27 (−4.38%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GYRE with… →

GYRE Key Statistics

As of Oct 21, 2026

Trading

Open: $6.21
Previous Close: $6.17
Day's Range: 5.86–6.21
52-Week Range: 5.44–9.14
Volume: 131.36K
Beta: 4.74

Valuation

Market Cap: $625.60M
P/E Ratio: unprofitable
Forward P/E: 98.33
P/S ratio: 5.70
EPS (ttm): −0.25

Financials (FY)

Revenue (FY): $116.59M+10.24%
Net Income (FY): $5.03M−58.40%
Profit margin: −19.33%
Shares Outstanding: 106.03M
1-Year Return: −29.09%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 114.83K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GYRE closed at $5.90, −29.09% over 1 year.

Gyre Therapeutics, Inc. (GYRE) has a market capitalization of $625.60M.

In fiscal 2025, GYRE reported revenue of $116.59M.

GYRE Stock Return by Calendar Year

Gyre Therapeutics, Inc. (GYRE) 10-year return: what $10,000 became

1 year: $10,000 $7,091; −29.09%
5 years: $10,000 $6,866; −31.34%
10 years: $10,000 $1,989; −80.11%

If you had invested $10,000 in Gyre Therapeutics, Inc. (GYRE) 10 years ago, at the close on October 21, 2016, it would have been worth $1,989 at the close on October 21, 2026: −80.11% in total, −14.91% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−85.58%+422.01%−16.43%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−16.43%
2025	−41.65%
2024	−52.90%
2023	+422.01%
2022	+121.54%
2021	−85.58%
2020	−7.34%
2019	−13.69%
2018	−42.16%
2017	+39.90%
2016 (partial year)	−56.08%

As of October 21, 2026.

GYRE Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$116.59M	$5.03M	4.3%
2024	$105.76M	$12.09M	11.4%
2023	$113.45M	−$92.93M	−81.9%
2022	$102.29M	$2.30M	2.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$116.59M	$111.17M	$11.49M	$5.03M	4.3%
2024	$105.76M	$101.87M	$16.23M	$12.09M	11.4%
2023	$113.45M	$108.81M	$19.21M	−$92.93M	−81.9%
2022	$102.29M	$97.50M	$9.20M	$2.30M	2.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GYRE Dividend History

$3.60−83.2% vs 2022

Dividends per share, 2023 · 1 payments

Year	Dividends per share	Payments	Change
2023	$3.60	1	−83.2%
2022	$21.45	1	—

Most recent payment: $3.60 per share, ex-dividend January 13, 2023. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

GYRE Valuation vs Biotechnology Median

Median of 608 stocks

Metric	GYRE	Biotechnology median	vs median
P/S ratio	5.70	13.30	57% below
Profit margin	−19.33%	−38.31%	19.0 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Gyre Therapeutics, Inc. (GYRE) is capitalised at $625.60M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 625.

The most recent close on file for GYRE is $5.90, dated October 21, 2026. That is −$0.27 (−4.38%) against the previous close. Over the past 52 weeks the price has ranged from $5.44 to $9.14. The latest close sits 8.46% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $116.59M. That is +10.24% against the prior fiscal year, when revenue was $105.76M. Net income for the same year was $5.03M. That is −58.40% against the prior fiscal year. The reported profit margin is −19.33%. That is 19 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are −0.25.

Across the 4 fiscal years on file, revenue moves from $102.29M in 2022 to $116.59M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 98.33. Measured against sales, the shares trade at 5.7 times revenue. On price-to-sales that is 57.16% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 4.74. Daily returns over the trailing 10 years annualize to a volatility of 136.08%. The trailing one-year total return is −29.09%. Measured over 10 years, that is −14.91% a year compounded.

Growth & Income

The dividend record for GYRE runs through 2023. Dividends are recorded for 2 calendar years; 2023 shows 1 payments totalling $3.60 a share. The year before, 2022, totalled $21.45 a share.

So far in 2026 the total return is −16.43%. The strongest complete calendar year on file is 2023 at +422.01%; the weakest is 2021 at −85.58%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Gyre Therapeutics, Inc. (GYRE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Gyre Therapeutics, Inc.	GYRE	$625.60M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Gyre Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Visit website →